NTRP - ニュ―ロトロ―プ (Neurotrope Inc.)

NTRPのニュース

   BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1  2020/06/10 12:00:00 Business Wire
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
   Neurotrope : Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease | MarketScreener  2020/05/28 13:56:12 MarketScreener
- New Phase 2 Study to Be Conducted in Collaboration with NIHUnder a $2.7 Million Grant- -Management to Host Investor Conference Call and Webcast Today at 11:00… | May 28, 2020
   Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding  2020/01/22 16:14:15 Benzinga
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com
   The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris  2019/09/10 11:36:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.
   Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment  2019/09/09 19:05:00 MarketWatch
Shares of Neurotrope Inc. plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company…
   BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1  2020/06/10 12:00:00 Business Wire
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
   Neurotrope : Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease | MarketScreener  2020/05/28 13:56:12 MarketScreener
- New Phase 2 Study to Be Conducted in Collaboration with NIHUnder a $2.7 Million Grant- -Management to Host Investor Conference Call and Webcast Today at 11:00… | May 28, 2020
   Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding  2020/01/22 16:14:15 Benzinga
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com
   The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris  2019/09/10 11:36:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.
   Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment  2019/09/09 19:05:00 MarketWatch
Shares of Neurotrope Inc. plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company…
   BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1  2020/06/10 12:00:00 Business Wire
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
   Neurotrope : Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease | MarketScreener  2020/05/28 13:56:12 MarketScreener
- New Phase 2 Study to Be Conducted in Collaboration with NIHUnder a $2.7 Million Grant- -Management to Host Investor Conference Call and Webcast Today at 11:00… | May 28, 2020
   Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding  2020/01/22 16:14:15 Benzinga
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com
   The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris  2019/09/10 11:36:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.
   Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment  2019/09/09 19:05:00 MarketWatch
Shares of Neurotrope Inc. plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company…

calendar